Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Michael O'Riordan

November 17, 2022

News Daily News

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Michael O'Riordan

August 08, 2022

News Daily News

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

Michael O'Riordan

March 15, 2022

News Daily News

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Yael L. Maxwell

February 22, 2022

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

Presentation AHA 2018

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Presenter: Sotirios Tsimikas

November 11, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Daily News

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Michael O'Riordan

January 09, 2018

News Daily News

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

Todd Neale

May 26, 2017

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

Advertisement

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Less Is More: Lp(a) Much More Atherogenic Than LDL

How Lp(a) Levels Compare With LDL-C in FH: Some Surprises

Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression

Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol

What Can Lp(a) Add to CAC for ASCVD Risk Prediction? New Insights

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Role of Lp(a) Still to Be Determined, but NHLBI Sees a Path Forward

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content